It is going to take more than RXMD's incremental growth to make this SP go up again. Even uplisting, updating the Midam issue or CV payback news will have modest effects. Expect it to keep declining until RXMD management has the true desire to do something about it. Rightfully so, they have their focus on the business and need the capital to grow it. Until there is a stock buyback or paid promo's, we are where we are. Buy the cheapies and hope your not sitting on them for a year or two as they decline.
News 
Market Data 
Discover 
